U.S. Markets open in 1 hr 58 mins

Panaxia Labs Israel Ltd (PNAX.TA)

Tel Aviv - Tel Aviv Delayed Price. Currency in ILA (0.01 ILS)
Add to watchlist
37.70+2.00 (+5.60%)
At close: 05:24PM IDT
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close35.70
Bid35.40 x N/A
Ask37.80 x N/A
Day's Range37.00 - 38.10
52 Week Range34.00 - 163.00
Avg. Volume222,597
Market Cap5.644B
Beta (5Y Monthly)-0.10
PE Ratio (TTM)N/A
EPS (TTM)-0.86
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJun 03, 2012
1y Target EstN/A
  • PR Newswire

    Panaxia announces production license of medical cannabis products in Malta

    Panaxia Global, the controlling owner of Panaxia Malta (operations) Ltd., a global pharma company that develops, manufactures and markets advanced medical cannabis products of pharmaceutical quality, announced today that it has received an official license from the health authorities in Malta to manufacture finished medical cannabis products.

  • PR Newswire

    Panaxia sums up 2021 with a growth of 38% in total revenues of its Israeli activity, including initial revenues from cannabis oils export of 5.6 million

    Dr. Dadi Segal, CEO of Panaxia Israel: "We conclude 2021 with double-digit revenue growth, including export revenues of approximately 5.6 million and 8% market share in the oils category in Germany. It was a launching year and a market penetration of the first product we have exported, clinically repellent and clinically backed. We are proud that at such an early stage, about a year after we first started exporting our premium oils to Germany, Panaxia ranks #3 in cannabis oil sales in Germany. A

  • PR Newswire

    Panaxia and Neuraxpharm: First export of medical cannabis sublingual tablets to France

    Panaxia Labs Israel Ltd. ("Panaxia Israel"), (TASE: PNAX), a global pharma company which develops, manufactures and markets progressive medical cannabis products in pharmaceutical quality, and Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the central nervous system (CNS), announced today a first export of medical cannabis sublingual tablets from Israel to France.